Targeting death receptors in cancer with Apo2L/TRAIL
SK Kelley, A Ashkenazi - Current opinion in pharmacology, 2004 - Elsevier
Unlike conventional cancer therapeutics, death receptor ligands trigger tumor cell apoptosis
independently of the p53 tumor suppressor gene, which frequently is inactivated in cancer.
The death receptor ligand Apo2 ligand/tumor necrosis factor-related apoptosis-inducing
ligand (Apo2L/TRAIL) offers promising therapeutic potential based on its ability to induce
apoptosis in various cancer cell lines with little toxicity toward normal cells. Moreover,
Apo2L/TRAIL displays single-agent activity and cooperates with chemotherapy or …
independently of the p53 tumor suppressor gene, which frequently is inactivated in cancer.
The death receptor ligand Apo2 ligand/tumor necrosis factor-related apoptosis-inducing
ligand (Apo2L/TRAIL) offers promising therapeutic potential based on its ability to induce
apoptosis in various cancer cell lines with little toxicity toward normal cells. Moreover,
Apo2L/TRAIL displays single-agent activity and cooperates with chemotherapy or …